Table 1.
Virus/vector | Percentage of integration sites
|
Description | |
---|---|---|---|
In genes* | In CpG islands‡ | ||
MLV§ | 43.3 | 17.7 | §§ Strong preference for transcript start sites |
HIV¶ | 65.2 | 1.5 | ¶¶ Strong preference for transcription units |
ASLV# | 42.9 | 2.7 | Weak preference for transcription units |
Foamy** | 28.6 | 9.9 | Modest preference for transcript start sites |
Random‡‡ | 34.1 | 2.6 | NA |
Within the transcribed region of Refseq genes, human genome build 35 (hg17).
In a CpG island or within 1 kilobase.
1757 HIV integrations in primary lung fibroblasts (426), PBMCs (487), SupT1 cells (504), H9 cells (215) and HeLa (125) cells from [20,22,24], as analyzed in [25].
480 Avian sarcoma-leukosis virus (ASLV) integrations in HeLa (181) and 293T-TVA cells (299) from [23,24], as analyzed in [25].
2829 Foamy integrations in normal human fibroblasts (1008) and CD34+ hematopoietic cells (1,821) [25].
10,000 randomly generated sites as previously described [25].
Strong as defined by > 15% and modest as defined by between 10 and 12% of integrants within 2.5 kb of transcript start sites respectively.
Strong as defined by > 60% and weak as defined by < 45% of integrants within transcription units respectively.
NA: Not applicable.